Drawing for MYMRD

USPTO serial 86543080

MYMRD

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
DELANEY, ZHALEH SYBIL
Law office
TMO LAW OFFICE 116 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with MYMRD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ian W. Gillies

IAN W. GILLIES Knobbe Martens Olson & Bear Llp2040 Main St Fl 14Irvine, CA 92614-8214UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific and research use, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of chemical and biological reagents for nonmedical purposes; diagnostic reagents for scientific and research use; diagnostic assays for research, clinical research, and laboratory research useACTIVE—
005Assays for the treatment or diagnosis of disease; medical diagnostic reagents, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic kits comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic reagent kits comprised of chemical and biological reagents for the treatment, monitoring and diagnosis of disease; medical diagnostic reagent kits comprised of medical reagents for clinical or medical use; medical diagnostic assays for the treatment and diagnosis of disease; medical diagnostic assays for testing of bodily fluidsACTIVE—
042DNA analysis services for scientific research purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assaysACTIVE—
044DNA screening for medical purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assaysACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 16, 2015MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 16, 2015ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 17, 2015GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Mar 17, 2015GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Mar 17, 2015CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Mar 11, 2015DOCKASSIGNED TO EXAMINER—
Mar 9, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 26, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance